Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Long-Term Capital Lease Obligation : $29.7 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Amphastar Pharmaceuticals Long-Term Capital Lease Obligation?

Amphastar Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $29.7 Mil.

Amphastar Pharmaceuticals's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($24.4 Mil) to Sep. 2023 ($30.2 Mil) but then declined from Sep. 2023 ($30.2 Mil) to Dec. 2023 ($29.7 Mil).

Amphastar Pharmaceuticals's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($24.7 Mil) to Dec. 2022 ($23.7 Mil) but then increased from Dec. 2022 ($23.7 Mil) to Dec. 2023 ($29.7 Mil).

Amphastar Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Amphastar Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Long-Term Capital Lease Obligation Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

16.32

17.46

24.70

23.69

29.72

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															23.99	24.41	30.20	29.72	28.74

Amphastar Pharmaceuticals (NAS:AMPH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Amphastar Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (NAS:AMPH) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

29A:Germany 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Executives

Mary Z. Luo	director, 10 percent owner, officer: COO and Chief Scientist	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Floyd F. Petersen	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Rong Zhou	officer: EVP, Production	C/O AMPHASTAR PHARMACEUTICALS INC., 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Richard K Prins	director
William J Peters	officer: CFO, SVP & Treasurer	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Yakob Liawatidewi	officer: SVP Corp Admin Center	C/O AMPHASTAR PHARMACEUTICALS INC, 11570 SIXTH STREET, RANCHO CUCAMONGA CA 91730
Michael A Zasloff	director
Gayle Deflin	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Diane G. Gerst	officer: EVP, QA & Regulatory Affairs	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Howard Lee	director	13F-2, NO. 36, LANE 48, SECTION 3, NAN-JING EAST ROAD, TAIPEI, TAIWAN F4 00000
Jack Y. Zhang	director, 10 percent owner, officer: CEO & Chief Scientific Officer	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
David Maris	director	C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Richard Koo	director	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Jason B. Shandell	director, officer: President	11570 6TH STREET, RANCHO CUCAMONGA CA 91730
Applied Physics & Chemistry Laboratories, Inc.	10 percent owner	13760 MAGNOLIA AVENUE, CHINO CA 91710